Journal article
Targeting GM-CSF in inflammatory and autoimmune disorders
AA Achuthan, KMC Lee, JA Hamilton
Seminars in Immunology | Published : 2021
Abstract
Granulocyte macrophage-colony stimulating factor (GM-CSF) was originally identified as a growth factor for its ability to promote the proliferation and differentiation in vitro of bone marrow progenitor cells into granulocytes and macrophages. Many preclinical studies, using GM-CSF deletion or depletion approaches, have demonstrated that GM-CSF has a wide range of biological functions, including the mediation of inflammation and pain, indicating that it can be a potential target in many inflammatory and autoimmune conditions. This review provides a brief overview of GM-CSF biology and signaling, and summarizes the findings from preclinical models of a range of inflammatory and autoimmune dis..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The work was supported by a grant from the National Health and Medical Research Council of Australia (1159901) to A.A.A. The authors are employed by the University of Melbourne, which has licensed patented technology relating to therapeutically targeting GM-CSF to MorphoSys AG, Germany. The authors declare no other competing financial interests. The illustrations were created with BioRender.com.